COLLEGIUM PHARMACEUTICAL, INC COLL
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
1.76
Altman Z″ — distress risk · grey
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $780.6M | $62.9M | $463.3M | $327.6M | $301.7M |
| 2024 | $631.4M | $69.2M | $377.3M | $203.3M | $228.8M |
| 2023 | $566.8M | $48.2M | $326.2M | $274.3M | $195.4M |
| 2022 | $463.9M | -$25.0M | $209.5M | $122.6M | $194.8M |
| 2021 | $276.9M | $71.5M | $150.6M | $101.6M | $202.9M |
| 2020 | $310.0M | $26.8M | $179.8M | $88.4M | $186.0M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 1.76 (grey)
- Working capital / assets 0.152
- Retained earnings / assets -0.061
- EBIT / assets 0.108
- Equity / liabilities 0.223
Source: SEC EDGAR filings · CIK 0001267565 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.